Liver Disease
Conference Coverage
Liver cancer without cirrhosis surprisingly common: Is NAFLD the cause?
Key clinical point: A significant proportion of NAFLD-related HCC patients have no cirrhosis at presentation, so clinicians need to maintain a...
News
Hepatitis B screening recommended for high-risk patients
Key clinical point: HBV screening is appropriate in all at-risk populations.Major finding: Physicians should screen all adolescents and adults at...
Conference Coverage
PEARL-II: Oral ‘3D’ regimen effective in hepatitis C with prior treatment failure
Major finding: Noncirrhotic patients with hepatitis C genotype 1b disease who had failed previous pegylated interferon–based therapy had a 100%...
Conference Coverage
VIDEO: PCPs fuzzy on HCC surveillance in cirrhosis
Conference Coverage
VIDEO: Oral drugs tackle hepatitis C genotypes 2, 3
Conference Coverage
Interferon-free regimen improves response in HCV
Major finding: For patients with genotype 1a infection, SVR occurred in 97% with ribavirin and 90.2% without ribavirin.
Conference Coverage
Sofosbuvir-ribavirin treats hepatitis C virus genotypes 2, 3
Major finding: Sustained virologic response occurred in 93% after 12 weeks of treatment for genotype 2 and in 85% after 24 weeks of therapy for...
Conference Coverage
NAFLD mortality higher in normal weight patients
Major finding: Among 483 patients with liver biopsies before 2005, 9 of the 32 (28%) lean patients died, compared with 62 of the 451 (14%) who...
From the AGA Journals
Liver transplant exceptions deserve fresh look
Major finding: Liver transplant recipients with hepatopulmonary syndrome have success similar to that of other transplant candidates, unless...
News
Simeprevir and sofosbuvir combo offers high SVR rates
Major finding: SVR12 rates were 93% and 93% after 12 weeks and 93% and 100% after 24 weeks of dual treatment with or without ribavirin.Data source...